AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of ...

AstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals. The British-Swedish pharma giant on Tuesday said ...

In July, sales in AstraZeneca's top business, oncology, grew 19 per cent at constant currency rates to $5.3billion (£4.1billion) and accounted for 41 per cent of the total, while its rare disease ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late ...

AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or metastatic triple-negative breast cancer did not meet primary endpoints ...

(Reuters) - London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve ...

AstraZeneca said on Monday its drug Imfinzi failed to meet the main goal of improving overall survival compared with platinum-based chemotherapy as a monotherapy treatment of patients with late ...

AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial. Analysts anticipate a sales potential for the drug of $1.5 billion in 2030. By . Helena Smolak. Share. Resize.

AstraZeneca Pharma India has received approval from India's drug regulator to expand the use of a breast cancer treatment that could bring new hope to many women with advanced disease. The ...

AstraZeneca's breast cancer drug combination fails in late-stage trial Triple-negative breast cancer remains one of the most challenging forms of disease to treat due to the lack of known ...